Active Ingredient History

  • Now
Seliciclib is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study.   Wikipedia

  • SMILES: CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1
  • Mol. Mass: 354.46
  • ALogP: 3.2
  • ChEMBL Molecule:
More Chemistry
2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine | (2r)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol | al-39256 | cyc202 | cyc 202 | cyc-202 | roscovitine | r-roscovitine | seliciclib


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue